

=> d his

(FILE 'HOME' ENTERED AT 17:52:23 ON 07 APR 2006)

FILE 'CAPLUS, MEDLINE' ENTERED AT 17:52:32 ON 07 APR 2006

L1	0	S	FEXOFENADINE	(P)	LACTOSE	(P)	HYDROXYPROPYL CELLULOSE
L2	1	S	FEXOFENADINE	(P)	LACTOSE	(P)	LOW-SUBSTITUTE?
L3	0	S	FEXOFENADINE	(P)	LACTOSE	(P)	CELLULOSE
L4	1	S	FEXOFENADINE	(P)	LACTOSE	(P)	HYDROXYPROPYL CELLULOSE
L5	1	S	FEXOFENADINE	(P)	LACTOSE	(P)	CELLULOSE
L6	1	S	FEXOFENADINE	(P)	LACTOSE	(P)	CELLULOSE
L7	8	S	FEXOFENADINE	(P)	LACTOSE		
L8	10	S	FEXOFENADINE	(P)	CELLULOSE		
L9	8	S	FEXOFENADINE	(P)	?CELLULOSE		
L10	8	S	FEXOFENADINE	(P)	?LACTOSE		

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:136558 CAPLUS

DOCUMENT NUMBER: 142:225793

TITLE: A process for preparing fexofenadine composition

INVENTOR(S): Nandi, Indranil; Patel, Ashish Anilbhai; Sadatrezaei, Mohsen; Davila, Pablo; Khanapure, Virendra Maheshappa; Durugkar, Surendra Wasudeorao

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013987	A1	20050217	WO 2004-EP8600	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005065183	A1	20050324	US 2003-631874	20030731
AU 2004262914	A1	20050217	AU 2004-262914	20040730
PRIORITY APPLN. INFO.:			US 2003-631874	A 20030731
			WO 2004-EP8600	W 20040730

AB A pharmaceutical composition comprising **fexofenadine** or a pharmaceutically acceptable salt thereof, **lactose**, a low **-substituted** hydroxypropyl cellulose and optionally other excipients is disclosed. The **fexofenadine** compns. of the invention exhibit improved bioavailability as expressed as Cmax, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma concentration time curve. For example, a **fexofenadine** tablet composition was prepared by wet granulation of a powder blend containing **fexofenadine-HCl** 180 g, **lactose** 348 g, and hydroxypropyl cellulose 30 g. Wet granules were dried and then passed through 20 mesh, blended with crospovidone 36 g, and then with magnesium stearate 6 g. The lubricated granules were then compressed into tablets. The compressed tablets were optionally film coated with a composition containing HPMC 70%,

TiO2

19.2%, propylene glycol 10%, yellow iron oxide 0.5%, and red iron oxide 0.3% to a total weight of 618 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:228702 CAPLUS

DOCUMENT NUMBER: 134:242705

TITLE: Preparation of controlled drug delivery system  
containing pseudoephedrine and a long acting  
antihistamine

INVENTOR(S): Jain, Girish Kumar; Rampal, Ashok; Sen, Himadri

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021168	A1	20010329	WO 2000-IB1315	20000918
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6267986	B1	20010731	US 1999-405643	19990924
EP 1217997	A1	20020703	EP 2000-958919	20000918
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			

PRIORITY APPLN. INFO.: US 1999-405643 A 19990924  
WO 2000-IB1315 W 20000918

AB This invention relates to a process for the preparation of a controlled release pharmaceutical composition comprising 2 discrete zones wherein the first discrete zone comprises therapeutically effective amount of pseudoephedrine or its pharmaceutically acceptable salt as active ingredient and the second discrete zone comprises a therapeutically effective amount of a long-acting antihistamine selected from the group consisting of loratadine, azatadine, **fexofenadine**, terfenadine, cetirizine, astemizole, and levocabastine, or their pharmaceutically acceptable salt as active ingredient. Thus, the first tablet layer was formed from pseudoephedrine sulfate 40.00, Keltrol TF 33.33, Keltone HVCR 13.33, CaCO<sub>3</sub> 8.83, Mg stearate 1.00, and Aerosil-200 1.00%. The second tablet layer was obtained from loratadine 5.00, **lactose** 47.50, Avicel PH-101 33.25, FD&C-10 0.50, corn starch 10.00, starch (for paste) 3.00, and Mg stearate 0.75% by weight The 2 layers were compressed into tablets.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:833069 CAPLUS  
DOCUMENT NUMBER: 135:376743  
TITLE: Packaging regimen of pseudoephedrine and fexofenadine  
INVENTOR(S): Randall, Douglas E.; Nicholas, James M.  
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA  
SOURCE: PCT Int. Appl., 27 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085148	A2	20011115	WO 2001-US14353	20010503
WO 2001085148	A3	20020801		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001061165	A5	20011120	AU 2001-61165	20010503
US 2002022639	A1	20020221	US 2001-848463	20010503
JP 2003532671	T2	20031105	JP 2001-581802	20010503
PRIORITY APPLN. INFO.:			US 2000-202323P	P 20000505
			GB 2000-30802	A 20001218
			WO 2001-US14353	W 20010503

AB A package for dispensing 2 or more drugs is described and claimed. In one of the embodiments of this invention, the package dispenses essentially: a container to dispense drug (A) having therapeutically effective amts. of fexofenadine or its salt; and a container to dispense drug (B) containing a combination of fexofenadine and pseudoephedrine or their salts. Various preferred embodiments of the package of this invention are also described and claimed. Thus, the package of a bilayer tablet comprises a first discrete zone containing 25-33% pseudoephedrine, and a first carrier base material. The first carrier base material comprises a mixture of carnauba wax 66-74% and a suitable antiadherent 0.50-1.50 by weight of pseudoephedrine.

L7 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:611930 CAPLUS  
DOCUMENT NUMBER: 143:139149  
TITLE: Oral pharmaceutical compositions  
INVENTOR(S): Mungre, Ashish Prabhakar; Nabar, Manisha Saiprasad  
PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India  
SOURCE: PCT Int. Appl., 17 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005062722	A2	20050714	WO 2004-IN362	20041122
WO 2005062722	A3	20050922		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: IN 2003-MU1204 A 20031121  
AB The present invention provides an immediate release oral pharmaceutical composition comprising **fexofenadine** or its salts, a dissoln. enhancing amount of a thermomelting binding agent and excipients. Tablets contained **fexofenadine-HCl** 30.0, **lactose** 50.0, Prosolv SMCC-90 17.5, SLS 1.0, colloidal silica 0.5, and Mg stearate 1.0%.

L7 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:430016 CAPLUS  
DOCUMENT NUMBER: 143:109441  
TITLE: The efficacy of short-term administration of 3 antihistamines vs. placebo under natural exposure to Japanese cedar pollen  
AUTHOR(S): Hyo, Sawako; Fujieda, Shigeharu; Kawada, Ryo; Kitazawa, Shikifumi; Takenaka, Hiroshi  
CORPORATE SOURCE: Department of Otorhinolaryngology, Osaka Medical College, Osaka, Japan  
SOURCE: Annals of Allergy, Asthma, & Immunology (2005), 94(4), 457-464  
CODEN: ALAIF6; ISSN: 1081-1206  
PUBLISHER: American College of Allergy, Asthma, & Immunology  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Japanese cedar pollinosis, a common disease with morbidity of approx. 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-mo period. The aim was to investigate the effectiveness of cetirizine hydrochloride, loratadine, and **fexofenadine** hydrochloride in reducing pollinosis symptoms induced while walking in a park during the pollen season. A randomized, double-masked, placebo-controlled trial was conducted in 113 individuals with Japanese cedar pollinosis during 2 days in Mar. 2003 in Osaka Expo Park, Osaka, Japan. Participants (aged 20-57 years) were divided into 4 groups according to treatment assignment: cetirizine hydrochloride, 10 mg/d; **fexofenadine** hydrochloride, 120 mg/d; loratadine, 10 mg/d; and placebo (**lactose**), twice daily. Symptoms were recorded

hourly during the study. Furthermore, all the patients completed the Japanese version of the Rhinoconjunctivitis Quality of Life Questionnaire before and after the trial. Self-evaluated symptom scores in all 3 active treatment groups showed significant improvements compared with the placebo group. Furthermore, the cetirizine group showed significant improvement in the domains of frequency of nose blowing and nasal obstruction compared with placebo. In addition, improvement in Japanese Rhinoconjunctivitis Quality of Life Questionnaire scores was higher in the cetirizine group than in the loratadine and placebo groups. Cetirizine seems to be more effective than **fexofenadine** and loratadine at reducing subjective symptoms in this study population.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:219717 CAPLUS  
 DOCUMENT NUMBER: 142:266844  
 TITLE: Orodispersible tablets containing fexofenadine  
 INVENTOR(S): Faham, Amina; Marechal, Dominique; Chenevier, Philippe  
 PATENT ASSIGNEE(S): Can.  
 SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 995,975.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005053654	A1	20050310	US 2004-495007	20041025
US 2003099700	A1	20030529	US 2001-995975	20011116
US 6723348	B2	20040420		
WO 2003041683	A2	20030522	WO 2002-EP14917	20021114
WO 2003041683	A3	20030828		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-995975 A2 20011116  
 WO 2002-EP14917 W 20021114

AB Orodispersible tablets disintegrate in the buccal cavity upon contact with saliva by the formation of an easy-to-swallow suspension, in <60 s, preferably in <40 s, containing fexofenadine in coated granules, and a mixture of excipients. The formulation also comprises at least 1 disintegrant, a soluble diluent, a lubricant and optionally a swelling agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of the orodispersible tablets in the treatment of seasonal allergic rhinitis. Thus, 500 g fexofenadine-HCl was mixed with 15 g Syloid FP244 and granulated with a mixture of Eudragit EPO/Eudragit NE30D in water at 16%.

L7 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:136558 CAPLUS  
 DOCUMENT NUMBER: 142:225793  
 TITLE: A process for preparing fexofenadine composition  
 INVENTOR(S): Nandi, Indranil; Patel, Ashish Anilbhai; Sadatrezaei, Mohsen; Davila, Pablo; Khanapure, Virendra Maheshappa;

PATENT ASSIGNEE(S): Durugkar, Surendra Wasudeorao  
 SOURCE: Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
 PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013987	A1	20050217	WO 2004-EP8600	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005065183	A1	20050324	US 2003-631874	20030731
AU 2004262914	A1	20050217	AU 2004-262914	20040730
PRIORITY APPLN. INFO.:			US 2003-631874	A 20030731
			WO 2004-EP8600	W 20040730

AB A pharmaceutical composition comprising **fexofenadine** or a pharmaceutically acceptable salt thereof, **lactose**, a low-substituted hydroxypropyl cellulose and optionally other excipients is disclosed. The **fexofenadine** compns. of the invention exhibit improved bioavailability as expressed as Cmax, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma concentration time curve. For example, a **fexofenadine** tablet composition was prepared by wet granulation of a powder blend containing **fexofenadine-HCl** 180 g, **lactose** 348 g, and hydroxypropyl cellulose 30 g. Wet granules were dried and then passed through 20 mesh, blended with crospovidone 36 g, and then with magnesium stearate 6 g. The lubricated granules were then compressed into tablets. The compressed tablets were optionally film coated with a composition containing HPMC 70%,

TiO2

19.2%, propylene glycol 10%, yellow iron oxide 0.5%, and red iron oxide 0.3% to a total weight of 618 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:396696 CAPLUS  
 DOCUMENT NUMBER: 138:390960  
 TITLE: Orodispersible tablets containing **fexofenadine**  
 INVENTOR(S): Faham, Amina; Marechal, Dominique; Chenevier, Philippe  
 PATENT ASSIGNEE(S): Ethypharm, Fr.  
 SOURCE: PCT Int. Appl., 33 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003041683	A2	20030522	WO 2002-EP14917	20021114
WO 2003041683	A3	20030828		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003099700 A1 20030529 US 2001-995975 20011116  
 US 6723348 B2 20040420  
 CA 2466580 AA 20030522 CA 2002-2466580 20021114  
 EP 1458387 A2 20040922 EP 2002-803040 20021114  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK  
 JP 2005513008 T2 20050512 JP 2003-543570 20021114  
 US 2005053654 A1 20050310 US 2004-495007 20041025  
 PRIORITY APPLN. INFO.: US 2001-995975 A 20011116  
 WO 2002-EP14917 W 20021114

AB The present invention concerns orodispersible tablets, which are able to disintegrate in the buccal cavity upon contact with saliva by formation of an easy-to-swallow suspension, in less than 60 s, preferably in less than 40 s, containing fexofenadine in the form of coated granules, and a mixture of excipients comprising at least one disintegrating agent, a soluble diluent agent, a lubricant and optionally a swelling agent, a permeabilizing agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of said orodispersible tablets in the treatment of seasonal allergic rhinitis. Granules were prepared containing fexofenadine-HCl, Syloid FP 244, Eudragit EPO and Eudragit NE30 D. The granules were coated with a mixture of Eudragit EPO/Eudragit NE30D (50:50) and the dissoln. rates of the coated granules were determined

L7 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2001:833069 CAPLUS  
 DOCUMENT NUMBER: 135:376743  
 TITLE: Packaging regimen of pseudoephedrine and fexofenadine  
 INVENTOR(S): Randall, Douglas E.; Nicholas, James M.  
 PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA  
 SOURCE: PCT Int. Appl., 27 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085148	A2	20011115	WO 2001-US14353	20010503
WO 2001085148	A3	20020801		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001061165	A5	20011120	AU 2001-61165	20010503
US 2002022639	A1	20020221	US 2001-848463	20010503
JP 2003532671	T2	20031105	JP 2001-581802	20010503
PRIORITY APPLN. INFO.:			US 2000-202323P	P 20000505
			GB 2000-30802	A 20001218

AB A package for dispensing 2 or more drugs is described and claimed. In one of the embodiments of this invention, the package dispenses essentially: a container to dispense drug (A) having therapeutically effective amts. of fexofenadine or its salt; and a container to dispense drug (B) containing a combination of fexofenadine and pseudoephedrine or their salts. Various preferred embodiments of the package of this invention are also described and claimed. Thus, the package of a bilayer tablet comprises a first discrete zone containing 25-33% pseudoephedrine, and a first carrier base material. The first carrier base material comprises a mixture of carnauba wax 66-74% and a suitable antiadherent 0.50-1.50 by weight of pseudoephedrine.

L7 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:228702 CAPLUS

DOCUMENT NUMBER: 134:242705

TITLE: Preparation of controlled drug delivery system containing pseudoephedrine and a long acting antihistamine

INVENTOR(S): Jain, Girish Kumar; Rampal, Ashok; Sen, Himadri

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021168	A1	20010329	WO 2000-IB1315	20000918
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6267986	B1	20010731	US 1999-405643	19990924
EP 1217997	A1	20020703	EP 2000-958919	20000918
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			

PRIORITY APPLN. INFO.: US 1999-405643 A 19990924  
WO 2000-IB1315 W 20000918

AB This invention relates to a process for the preparation of a controlled release pharmaceutical composition comprising 2 discrete zones wherein the first discrete zone comprises therapeutically effective amount of pseudoephedrine or its pharmaceutically acceptable salt as active ingredient and the second discrete zone comprises a therapeutically effective amount of a long-acting antihistamine selected from the group consisting of loratadine, azatadine, **fexofenadine**, terfenadine, cetirizine, astemizole, and levocabastine, or their pharmaceutically acceptable salt as active ingredient. Thus, the first tablet layer was formed from pseudoephedrine sulfate 40.00, Keltrol TF 33.33, Keltone HVCR 13.33, CaCO<sub>3</sub> 8.83, Mg stearate 1.00, and Aerosil-200 1.00%. The second tablet layer was obtained from loratadine 5.00, lactose 47.50, Avicel PH-101 33.25, FD&C-10 0.50, corn starch 10.00, starch (for paste) 3.00, and Mg stearate 0.75% by weight. The 2 layers were compressed into tablets.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 8 MEDLINE on STN

ACCESSION NUMBER: 2005238475 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 15875527  
 TITLE: The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen.  
 AUTHOR: Hyo Sawako; Fujieda Shigeharu; Kawada Ryo; Kitazawa Shikifumi; Takenaka Hiroshi  
 CORPORATE SOURCE: Department of Otorhinolaryngology, Osaka Medical College, Osaka, Japan.. oto039@poh.osaka-med.ac.jp  
 SOURCE: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, (2005 Apr) Vol. 94, No. 4, pp. 457-64. Journal code: 9503580. ISSN: 1081-1206.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200505  
 ENTRY DATE: Entered STN: 20050510  
 Last Updated on STN: 20050525  
 Entered Medline: 20050524

AB BACKGROUND: Japanese cedar pollinosis, a common disease with morbidity of approximately 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-month period. OBJECTIVE: To investigate the effectiveness of cetirizine hydrochloride, loratadine, and **fexofenadine** hydrochloride in reducing pollinosis symptoms induced while walking in a park during the pollen season. METHODS: A randomized, double-masked, placebo-controlled trial was conducted in 113 individuals with Japanese cedar pollinosis during 2 days in March 2003 in Osaka Expo Park, Osaka, Japan. Participants (aged 20-57 years) were divided into 4 groups according to treatment assignment: cetirizine hydrochloride, 10 mg/d; **fexofenadine** hydrochloride, 120 mg/d; loratadine, 10 mg/d; and placebo (**lactose**), twice daily. Symptoms were recorded hourly during the study. Furthermore, all the patients completed the Japanese version of the Rhinoconjunctivitis Quality of Life Questionnaire before and after the trial. RESULTS: Self-evaluated symptom scores in all 3 active treatment groups showed significant improvements compared with the placebo group. Furthermore, the cetirizine group showed significant improvement in the domains of frequency of nose blowing and nasal obstruction compared with placebo. In addition, improvement in Japanese Rhinoconjunctivitis Quality of Life Questionnaire scores was higher in the cetirizine group than in the loratadine and placebo groups. CONCLUSION: Cetirizine seems to be more effective than **fexofenadine** and loratadine at reducing subjective symptoms in this study population.

L8 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:219717 CAPLUS  
DOCUMENT NUMBER: 142:266844  
TITLE: Orodispersible tablets containing fexofenadine  
INVENTOR(S): Faham, Amina; Marechal, Dominique; Chenevier, Philippe  
PATENT ASSIGNEE(S): Can.  
SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S.  
Ser. No. 995,975.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005053654	A1	20050310	US 2004-495007	20041025
US 2003099700	A1	20030529	US 2001-995975	20011116
US 6723348	B2	20040420		
WO 2003041683	A2	20030522	WO 2002-EP14917	20021114
WO 2003041683	A3	20030828		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-995975 A2 20011116  
WO 2002-EP14917 W 20021114

AB Orodispersible tablets disintegrate in the buccal cavity upon contact with saliva by the formation of an easy-to-swallow suspension, in <60 s, preferably in <40 s, containing fexofenadine in coated granules, and a mixture of excipients. The formulation also comprises at least 1 disintegrant, a soluble diluent, a lubricant and optionally a swelling agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of the orodispersible tablets in the treatment of seasonal allergic rhinitis. Thus, 500 g fexofenadine-HCl was mixed with 15 g Syloid FP244 and granulated with a mixture of Eudragit EPO/Eudragit NE30D in water at 16%.

L8 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:136558 CAPLUS  
DOCUMENT NUMBER: 142:225793  
TITLE: A process for preparing fexofenadine composition  
INVENTOR(S): Nandi, Indranil; Patel, Ashish Anilbhai; Sadatrezaei, Mohsen; Davila, Pablo; Khanapure, Virendra Maheshappa; Durugkar, Surendra Wasudeorao  
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
SOURCE: PCT Int. Appl., 31 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013987	A1	20050217	WO 2004-EP8600	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

US 2005065183 A1 20050324 US 2003-631874 20030731  
 AU 2004262914 A1 20050217 AU 2004-262914 20040730  
 PRIORITY APPLN. INFO.: US 2003-631874 A 20030731  
 WO 2004-EP8600 W 20040730

AB A pharmaceutical composition comprising **fexofenadine** or a pharmaceutically acceptable salt thereof, lactose, a low-substituted hydroxypropyl cellulose and optionally other excipients is disclosed. The **fexofenadine** compns. of the invention exhibit improved bioavailability as expressed as Cmax, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma concentration time curve. For example, a **fexofenadine** tablet composition was prepared by wet granulation of a powder blend containing **fexofenadine-HCl** 180 g, lactose 348 g, and hydroxypropyl cellulose 30 g. Wet granules were dried and then passed through 20 mesh, blended with crospovidone 36 g, and then with magnesium stearate 6 g. The lubricated granules were then compressed into tablets. The compressed tablets were optionally film coated with a composition containing

HPMC

70%, TiO2 19.2%, propylene glycol 10%, yellow iron oxide 0.5%, and red iron oxide 0.3% to a total weight of 618 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1885 CAPLUS

DOCUMENT NUMBER: 142:79974

TITLE: Soft tablet containing high molecular weight cellulose

INVENTOR(S): Wynn, David; Parikh, Nick

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 8 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265373	A1	20041230	US 2003-608681	20030627
CA 2472432	AA	20041227	CA 2004-2472432	20040625
EP 1498114	A1	20050119	EP 2004-253844	20040625

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.: US 2003-607766 A 20030627  
 US 2003-608681 A 20030627

AB The invention relates to an immediate-release tablet capable of being chewed or disintegrated in the oral cavity, which comprises an active ingredient having an optional taste masking coating, and a matrix comprising hydroxyalkyl cellulose having a weight average mol. weight of 60,000-5,000,000. The tablet has exceptionally good mouth-feel and stability. Thus, a coating solution contained cellulose acetate 43, Hypromellose phthalate 53, and Polysorbate-80 4%. Ibuprofen granules were obtained in

the conventional manner and were then coated with the above taste-masking solution

L8 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:993 CAPLUS  
DOCUMENT NUMBER: 142:79963  
TITLE: Soft tablets containing high molecular weight celluloses  
INVENTOR(S): Wynn, David; Parikh, Nick  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 9 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265372	A1	20041230	US 2003-607766	20030627
CA 2472432	AA	20041227	CA 2004-2472432	20040625
EP 1491184	A1	20041229	EP 2004-253843	20040625

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.: US 2003-607766 A 20030627  
US 2003-608681 A 20030627

AB An immediate release tablet capable of being chewed or subjected to disintegration in the oral cavity, comprises an active ingredient having an optional taste-masking coating, and a matrix comprising hydroxyalkyl cellulose having a weight average mol. weight of 60,000-5,000,000. The tablet has exceptionally good mouth-feel and stability. A coating solution was prepared by dispersing cellulose acetate 43, Hypromellose phthalate 53, and Polysorbate-80 4% in a solvent consisting of 90% acetone and 10% water under ambient conditions, so that the finished solution contained 10% of the coating materials. Ibuprofen granules prepared in the conventional way were then coated with the above taste-masking solution High weight average mol. weight hydroxyalkyl cellulose-containing tablets had significantly less of a grittiness feel in the mouth in comparison to those tablets lacking the high weight average mol. weight hydroxyalkyl cellulose.

L8 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:818264 CAPLUS  
DOCUMENT NUMBER: 139:312454  
TITLE: Antihistaminic-decongestant combination containing fexofenadine hydrochloride polymorphs  
INVENTOR(S): Kamalakar, Talasila; Dash, Debashis; Srinivas, Irukula; Dhanorkar, Vipin Tatyasaheb; Mohan, Mailatur Sivaraman  
PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India  
SOURCE: PCT Int. Appl., 25 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084510	A1	20031016	WO 2002-IB1068	20020404

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,  
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,  
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2481377 AA 20031016 CA 2002-2481377 20020404  
 AU 2002253425 A1 20031020 AU 2002-253425 20020404  
 EP 1490034 A1 20041229 EP 2002-722540 20020404

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: WO 2002-IB1068 W 20020404

AB The present invention relates to pharmaceutical compns., especially tablets, of  
 antihistamine-decongestant combination. A novel polymorph of fexofenadine  
 or pharmaceutically accepted salts with at least one decongestant are in  
 the form of bilayered tablet. The preferred polymorphs are polymorph A  
 and polymorph X of fexofenadine hydrochloride.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:717514 CAPLUS

DOCUMENT NUMBER: 139:235427

TITLE: Tasteless, directly compressible, fast-dissolving  
 complexes and pharmaceutical formulations thereof

INVENTOR(S): Wadhwa, Hardeep

PATENT ASSIGNEE(S): India

SOURCE: U.S. Pat. Appl. Publ., 17 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003170310	A1	20030911	US 2003-383433	20030307
WO 2003075829	A2	20030918	WO 2003-IN48	20030307
WO 2003075829	A3	20041118		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,  
 PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,  
 UZ, VN, YU, ZA, ZM, ZW

EP 1454635 A1 20040908 EP 2004-5469 20040308

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.: IN 2002-DE207 A 20020308

US 2003-383433 A 20030307

AB A tasteless, granular, directly compressible, stable, fast-dissolving  
 complex of a bitter tasting basic drug, pharmaceutical formulations  
 comprising the tasteless complex of the basic drug and dosage forms  
 thereof are disclosed. The basic drug can be **fexofenadine**, and  
 the complex of the basic drug can be a **fexofenadine-carbomer**  
 complex. Processes for preparing, isolating and characterizing the tasteless  
 complex of the bitter tasting basic drug and processes for producing the  
 pharmaceutical formulations are also disclosed. Thus, tablets contained  
**fexofenadine-carbomer** complex 100, microcryst. **cellulose**  
 157, directly compressible aspartame 10, croscarmellose sodium 9, talc 3,  
 Mg stearate 3, flavor-mixed fruit 15, color-Sunset Yellow Lake 3  
 mg/tablet.

L8 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:396696 CAPLUS  
DOCUMENT NUMBER: 138:390960  
TITLE: Orodispersible tablets containing fexofenadine  
INVENTOR(S): Faham, Amina; Marechal, Dominique; Chenevier, Philippe  
PATENT ASSIGNEE(S): Ethypharm, Fr.  
SOURCE: PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003041683	A2	20030522	WO 2002-EP14917	20021114
WO 2003041683	A3	20030828		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003099700	A1	20030529	US 2001-995975	20011116
US 6723348	B2	20040420		
CA 2466580	AA	20030522	CA 2002-2466580	20021114
EP 1458387	A2	20040922	EP 2002-803040	20021114
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005513008	T2	20050512	JP 2003-543570	20021114
US 2005053654	A1	20050310	US 2004-495007	20041025
PRIORITY APPLN. INFO.:			US 2001-995975	A 20011116
			WO 2002-EP14917	W 20021114

AB The present invention concerns orodispersible tablets, which are able to disintegrate in the buccal cavity upon contact with saliva by formation of an easy-to-swallow suspension, in less than 60 s, preferably in less than 40 s, containing fexofenadine in the form of coated granules, and a mixture of excipients comprising at least one disintegrating agent, a soluble diluent agent, a lubricant and optionally a swelling agent, a permeabilizing agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of said orodispersible tablets in the treatment of seasonal allergic rhinitis. Granules were prepared containing fexofenadine-HCl, Syloid FP 244, Eudragit EPO and Eudragit NE30 D. The granules were coated with a mixture of Eudragit EPO/Eudragit NE30D (50:50) and the dissoln. rates of the coated granules were determined

L8 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:833069 CAPLUS  
DOCUMENT NUMBER: 135:376743  
TITLE: Packaging regimen of pseudoephedrine and fexofenadine  
INVENTOR(S): Randall, Douglas E.; Nicholas, James M.  
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA  
SOURCE: PCT Int. Appl., 27 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085148	A2	20011115	WO 2001-US14353	20010503
WO 2001085148	A3	20020801		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001061165	A5	20011120	AU 2001-61165	20010503
US 2002022639	A1	20020221	US 2001-848463	20010503
JP 2003532671	T2	20031105	JP 2001-581802	20010503
PRIORITY APPLN. INFO.:				
			US 2000-202323P	P 20000505
			GB 2000-30802	A 20001218
			WO 2001-US14353	W 20010503

AB A package for dispensing 2 or more drugs is described and claimed. In one of the embodiments of this invention, the package dispenses essentially: a container to dispense drug (A) having therapeutically effective amts. of fexofenadine or its salt; and a container to dispense drug (B) containing a combination of fexofenadine and pseudoephedrine or their salts. Various preferred embodiments of the package of this invention are also described and claimed. Thus, the package of a bilayer tablet comprises a first discrete zone containing 25-33% pseudoephedrine, and a first carrier base material. The first carrier base material comprises a mixture of carnauba wax 66-74% and a suitable antiadherent 0.50-1.50 by weight of pseudoephedrine.

L8 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2001:525909 CAPLUS  
 DOCUMENT NUMBER: 135:111997  
 TITLE: Osmotic device containing pseudoephedrine and an H1 antagonist  
 INVENTOR(S): Faour, Joaquina; Ricci, Marcelo A.  
 PATENT ASSIGNEE(S): Laboratorios Phoenix U.S.A., Inc., USA  
 SOURCE: PCT Int. Appl., 46 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051038	A1	20010719	WO 2001-US528	20010108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002102305	A1	20020801	US 2000-725655	20001129
US 6613357	B2	20030902		
CA 2396145	AA	20010719	CA 2001-2396145	20010108
EP 1246612	A1	20021009	EP 2001-900942	20010108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001007596	A	20021119	BR 2001-7596	20010108

PRIORITY APPLN. INFO.:

US 2000-175878P P 20000113  
US 2000-725655 A 20001129  
WO 2001-US528 W 20010108

AB The present invention provides an osmotic device containing controlled release pseudoephedrine in the core in combination with a rapid release H1 antagonist in an external coat. A wide range of H1 antagonist antihistamines, especially **fexofenadine**, can be used in this device. Particular embodiments of the invention provide osmotic devices having predetd. release profiles. One embodiment of the osmotic device includes an external coat that has been spray coated rather than compression coated onto the device. The device with spray coated external core is smaller and easier to swallow than the similar device having a compression coated external coat. The device is useful for the treatment of respiratory congestion related disorders and allergy related disorders. The present devices provide PS and an H1 antagonist according to specific release profiles in combination with specific formulations. Thus, tablets contained pseudoephedrine-HCl 24.00, osmagent 7-90, diluent 30-40, binder 40-60, plasticizer 0.5-5, glidant 0.5-5, and lubricant 5-10 mg in the core, cellulose ester, plasticizer, water-soluble polymer, filler, colorant, **fexofenadine**-HCl in the coating formulation.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:166514 CAPLUS  
DOCUMENT NUMBER: 130:213634  
TITLE: Bilayer tablets containing decongestants and piperidinoalkanol antihistamines  
INVENTOR(S): MacLaren, David D.; Lefler, John R.; Minish, Sharon K.  
PATENT ASSIGNEE(S): Hoechst Marion Roussel, Inc., USA  
SOURCE: PCT Int. Appl., 46 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909957	A1	19990304	WO 1998-US15237	19980721
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9885820	A1	19990316	AU 1998-85820	19980721
AU 725811	B2	20001019		
EP 998272	A1	20000510	EP 1998-937010	19980721
EP 998272	B1	20030502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200000517	T2	20000821	TR 2000-200000517	19980721
BR 9812001	A	20000926	BR 1998-12001	19980721
EE 200000098	A	20001215	EE 2000-200000098	19980721
EE 4294	B1	20040615		
NZ 501248	A	20010629	NZ 1998-501248	19980721
JP 2002511102	T2	20020409	JP 1999-514300	19980721
AT 238773	E	20030515	AT 1998-937010	19980721
RU 2207879	C2	20030710	RU 1999-125326	19980721
PT 998272	T	20030930	PT 1998-937010	19980721
ES 2192781	T3	20031016	ES 1998-937010	19980721

SK 283803	B6	20040203	SK 1999-1777	19980721
IL 133420	A1	20040725	IL 1998-133420	19980721
CZ 295461	B6	20050817	CZ 1999-4581	19980721
ZA 9807552	A	19990226	ZA 1998-7552	19980820
TW 570812	B	20040111	TW 1998-87113848	19980821
MX 9911699	A	20000531	MX 1999-11699	19991214
NO 2000000932	A	20000418	NO 2000-932	20000225
NO 318246	B1	20050221		
HK 1025904	A1	20030905	HK 2000-105074	20000815

PRIORITY APPLN. INFO.:

US 1997-920158	A	19970826
WO 1998-US15237	W	19980721

AB The present invention provides a pharmaceutical composition in the form of a bilayer tablet comprising: (a) a 1st discrete zone made with formulation which comprises a sympathomimetic drug or a salt thereof and a 1st carrier base comprising a mixture of carnauba wax and an antiadherent; wherein the 1st carrier base material provides a sustained-release of the sympathomimetic drug; and (b) a 2nd discrete zone made with formulation which comprises a piperidinoalkanol or a salt thereof and a 2nd carrier base material which contains a mixture of **cellulose**, pregelatinized starch, disintegrants, and lubricants; wherein the 2nd carrier base material provides an immediate release of the piperidinoalkanol. A bilayer tablet coated with Opadry YS 1-7006 contained (a) a sustained-release layer containing pseudoephedrine·HCl 120, carnauba wax 300, stearic acid flakes 4.899, colloidal SiO<sub>2</sub> 1.065 mg and (b) an immediate-release layer containing **fexofenadine** ·HCl 60, Avicel PH101 26, pregelatinized starch 60, Avicel PH102 190.5, croscarmellose Na 12, and Mg stearate 2.633 mg. The bilayer tablets exhibited sufficient phys. strength, content uniformity, and dissoln. profile.

REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT